Ellis Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Ellis Bio is an early-stage biotech tools company commercializing innovative epigenomic technologies originating from the lab of renowned scientist Dr. Chuan He. The company's core offering is its SuperMethyl™ product line, which includes kits for bisulfite conversion—a critical step in DNA methylation sequencing—that promise superior conversion efficiency, low DNA input requirements, and rapid workflows. With a lean, experienced team and a clear focus on the research tools market, Ellis Bio aims to capture share in the growing epigenomics sector by addressing key pain points in sample preparation.

BiologicsAntibodies

Technology Platform

Proprietary bisulfite conversion technologies (UBS/UMBS) for high-efficiency, low-degradation DNA methylation analysis, enabling high-accuracy sequencing from low-input samples and rapid workflows.

Opportunities

The growing demand for epigenomic analysis in research and diagnostics creates a large market for superior sample prep tools.

Ellis Bio's technology addresses critical pain points—low-input capability and speed—that can differentiate it from established competitors.

Success could lead to acquisition by a larger tools company or expansion into a full suite of epigenomic products.

Risk Factors

The company faces significant competition from large, entrenched players in the life science tools market.

As an early-stage venture, it is dependent on external funding and must successfully execute its commercial launch to generate traction and secure future capital.

Technology adoption requires validation from the research community, which is not guaranteed.

Competitive Landscape

Ellis Bio competes in the DNA methylation analysis segment against dominant reagent suppliers like Qiagen, Thermo Fisher Scientific, and Zymo Research, as well as newer niche players. Its competitive edge is based on claimed superior performance metrics (conversion efficiency, DNA preservation) from its academic-founder-derived technology. Market success will depend on proving these advantages in head-to-head comparisons and winning over cost- and protocol-sensitive researchers.

More companies in Diagnostics & Precision Medicine →More companies in United States →